Literature DB >> 24722156

Outcomes of unresected ground-glass nodules with cytology suspicious for adenocarcinoma.

Caroline M Gulati1, Andrew M Schreiner, Daniel M Libby, Jeffrey L Port, Nasser K Altorki, Brian D Gelbman.   

Abstract

BACKGROUND: Five-year survival rates for resected stage I adenocarcinoma approach 100%. Given previous studies describing the prolonged indolent natural history of ground-glass lesions suspicious for early adenocarcinoma, our purpose in this study was to determine if outcomes were different among patients who were observed for radiographic and biopsy suspected early adenocarcinoma compared with those who were resected immediately.
METHODS: We identified 63 patients with no prior history of lung adenocarcinoma who had undergone computer tomography-guided fine-needle aspiration of ground-glass opacities with cytology concerning for new early adenocarcinoma between January 2002 and December 2011. We compared the clinical outcomes of patients who were resected after abnormal cytology results and those who opted for watchful waiting.
RESULTS: Sixteen patients elected to observe their ground-glass nodules despite having suspicious cytology results, whereas 47 opted for immediate resection. Of the 16 observed patients, six (37.5%) ultimately demonstrated growth or increase solid component of the ground-glass nodule. Five of these patients elected for definitive therapy by surgical resection or radiation. There were no occurrences of distant metastasis or lung cancer-associated deaths in the observed group. Of the 47 resected patients, two developed metastatic disease, five developed new cancers in remaining lung, and three developed progression in existing ground-glass nodules.
CONCLUSIONS: Ground-glass lesions that were observed after biopsy did not demonstrate any increased rates of metastasis or cancer-related deaths and delayed resection does not seem to have a negative effect on outcomes.

Entities:  

Mesh:

Year:  2014        PMID: 24722156     DOI: 10.1097/JTO.0000000000000143

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  8 in total

1.  Recommendations from the European Society of Thoracic Surgeons (ESTS) regarding computed tomography screening for lung cancer in Europe.

Authors:  Jesper Holst Pedersen; Witold Rzyman; Giulia Veronesi; Thomas A D'Amico; Paul Van Schil; Laureano Molins; Gilbert Massard; Gaetano Rocco
Journal:  Eur J Cardiothorac Surg       Date:  2017-03-01       Impact factor: 4.191

2.  Adenocarcinoma in pure ground glass nodules: histological evidence of invasion and open debate on optimal management.

Authors:  Gianluca Milanese; Nicola Sverzellati; Ugo Pastorino; Mario Silva
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

3.  Single-staged uniportal VATS major pulmonary resection for bilateral synchronous multiple primary lung cancers.

Authors:  Chengwu Liu; Lin Ma; Feng Lin; Jiandong Mei; Qiang Pu; Hu Liao; Chenglin Guo; Lunxu Liu
Journal:  J Thorac Dis       Date:  2014-09       Impact factor: 2.895

4.  Noninvasive risk stratification of lung adenocarcinoma using quantitative computed tomography.

Authors:  Sushravya Raghunath; Fabien Maldonado; Srinivasan Rajagopalan; Ronald A Karwoski; Zackary S DePew; Brian J Bartholmai; Tobias Peikert; Richard A Robb
Journal:  J Thorac Oncol       Date:  2014-11       Impact factor: 15.609

5.  Lung Cancer Diagnosis by Fine Needle Aspiration Is Associated With Reduction in Resection of Nonmalignant Lung Nodules.

Authors:  Julie A Barta; Claudia I Henschke; Raja M Flores; Rowena Yip; David F Yankelevitz; Charles A Powell
Journal:  Ann Thorac Surg       Date:  2017-03-06       Impact factor: 5.102

Review 6.  Rationale for Lung Adenocarcinoma Prevention and Drug Development Based on Molecular Biology During Carcinogenesis.

Authors:  Hongming Zhang; Liting Guo; Jibei Chen
Journal:  Onco Targets Ther       Date:  2020-04-14       Impact factor: 4.147

Review 7.  Implications of the updated Lung CT Screening Reporting and Data System (Lung-RADS version 1.1) for lung cancer screening.

Authors:  Spencer C Dyer; Brian J Bartholmai; Chi Wan Koo
Journal:  J Thorac Dis       Date:  2020-11       Impact factor: 2.895

8.  Cost-Effectiveness Analysis of Lung Cancer Screening Accounting for the Effect of Indeterminate Findings.

Authors:  Iakovos Toumazis; Emily B Tsai; S Ayca Erdogan; Summer S Han; Wenshuai Wan; Ann Leung; Sylvia K Plevritis
Journal:  JNCI Cancer Spectr       Date:  2019-05-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.